|
1
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J PATHOL. 223:307–31. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y,
Zhang L, Ding C, Luo H, Li Y, et al: MicroRNAs activate gene
transcription epigenetically as an enhancer trigger. RNA Biol.
14:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dvinge H, Git A, Graf S, Salmon-Divon M,
Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al:
The shaping and functional consequences of the microRNA landscape
in breast cancer. Nature. 497:378–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cekaite L, Eide PW, Lind GE, Skotheim RI
and Lothe RA: MicroRNAs as growth regulators, their function and
biomarker status in colorectal cancer. Oncotarget. 7:6476–6505.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu CT, Lin WY, Chang YH, Lin PY, Chen WC
and Chen MF: DNMT1-dependent suppression of microRNA424 regulates
tumor progression in human bladder cancer. Oncotarget.
6:24119–24131. 2015.PubMed/NCBI
|
|
9
|
Zhou Y, An Q, Guo RX, Qiao YH, Li LX,
Zhang XY and Zhao XL: miR424-5p functions as an anti-oncogene in
cesrvical cancer cell growth by targeting KDM5B via the Notch
signaling pathway. Life Sci. 171:9–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Kong X, Li J, Luo Q, Li X, Shen
L, Chen L and Fang L: miR-96 promotes tumor proliferation and
invasion by targeting RECK in breast cancer. Oncol Rep.
31:1357–1363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rahmani-Nezhad S, Safavi M, Pordeli M,
Ardestani SK, Khosravani L, Pourshojaei Y, Mahdavi M, Emami S,
Foroumadi A and Shafiee A: Synthesis, in vitro cytotoxicity and
apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives
as potent anti-breast cancer agents. Eur J Med Chem. 86:562–569.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tirona MT, Sehgal R and Ballester O:
Prevention of breast cancer (part I): Epidemiology, risk factors,
and risk assessment tools. Cancer Invest. 28:743–750. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jahagirdar D, Purohit S, Jain A and Sharma
NK: Export of microRNAs: A bridge between breast carcinoma and
their neighboring cells. Front Oncol. 6:1472016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo Q, Li X, Li J, Kong X, Zhang J, Chen
L, Huang Y and Fang L: MiR-15a is underexpressed and inhibits the
cell cycle by targeting CCNE1 in breast cancer. Int J Oncol.
43:1212–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Kong X, Zhang J, Luo Q, Li X and
Fang L: Correction: MiRNA-26b inhibits proliferation by targeting
PTGS2 in breast cancer. Cancer Cell Int. 13:172013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Braza-Boils A, Mari-Alexandre J, Gilabert
J, Sanchez-Izquierdo D, Espana F, Estelles A and Gilabert-Estellés
J: MicroRNA expression profile in endometriosis: Its relation to
angiogenesis and fibrinolytic factors. Hum Reprod. 29:978–988.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gambari R, Brognara E, Spandidos DA and
Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor
miRNAs: New trends in the development of miRNA therapeutic
strategies in oncology (Review). Int J Oncol. 49:5–32. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jahagirdar D, Purohit S, Jain A and Sharma
NK: Export of microRNAs: A bridge between breast carcinoma and
their neighboring cells. Front Oncol. 6:1472016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bertoli G, Cava C and Castiglioni I: The
potential of miRNAs for diagnosis, treatment and monitoring of
breast cancer. Scand J Clin Lab Invest Suppl. 245:S34–S39. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for deiagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cava C, Bertoli G and Castiglioni I:
Integrating genetics and epigenetics in breast cancer: Biological
insights, experimental, computational methods and therapeutic
potential. BMC Syst Biol. 9:622015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee H, Kim KR, Cho NH, Hong SR, Jeong H,
Kwon SY, Park KH, An HJ, Kim TH, Kim I, et al: MicroRNA expression
profiling and Notch1 and Notch2 expression in minimal deviation
adenocarcinoma of uterine cervix. World J Surg Oncol. 12:3342014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nurse P, Masui Y and Hartwell L:
Understanding the cell cycle. Nat Med. 4:1103–1116. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–1566.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole vs letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sherr CJ, Beach D and Shapiro GI:
Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov.
6:353–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santamaria D, Barriere C, Cerqueira A,
Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and
Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle.
Nature. 448:811–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Li X, Kong X, Luo Q, Zhang J and
Fang L: MiRNA-26b inhibits cellular proliferation by targeting CDK8
in breast cancer. Int J Clin Exp Med. 7:558–565. 2014.PubMed/NCBI
|
|
32
|
Li XY, Luo QF, Wei CK, Li DF, Li J and
Fang L: MiRNA-107 inhibits proliferation and migration by targeting
CDK8 in breast cancer. Int J Clin Exp Med. 7:32–40. 2014.PubMed/NCBI
|
|
33
|
Li XY, Luo QF, Wei CK, Li DF and Fang L:
siRNA-mediated silencing of CDK8 inhibits proliferation and growth
in breast cancer cells. Int J Clin Exp Pathol. 7:92–100.
2013.PubMed/NCBI
|
|
34
|
Hua K, Jin J, Zhang H, Zhao B, Wu C, Xu H
and Fang L: MicroRNA-7 inhibits proliferation, migration and
invasion of thyroid papillary cancer cells via targeting CKS2. Int
J Oncol. 49:1531–1540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi P, Feng J and Chen C: Hippo pathway in
mammary gland development and breast cancer. Acta Biochim Biophys
Sin. 47:53–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang F, Steelman LS, Lee JT, Shelton JG,
Navolanic PM, Blalock WL, Franklin RA and McCubrey JA: Signal
transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine
receptors to transcription factors: Potential targeting for
therapeutic intervention. Leukemia. 17:1263–1293. 2003. View Article : Google Scholar : PubMed/NCBI
|
